Course of the International Normalized Ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon

被引:15
作者
Penning-van Beest, FJA
Rosendaal, FR
Grobbee, DE
van Meegen, E
Stricker, BHC
机构
[1] Erasmus Univ, Sch Med, Dept Internal Med 2, Pharmacoepidemiol Unit, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 CA Rotterdam, Netherlands
[3] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Haemostasis & Thrombosis Res Ctr, NL-2300 RA Leiden, Netherlands
[4] Univ Utrecht, Sch Med, Julius Ctr Patient Oriented Res, NL-3508 TC Utrecht, Netherlands
[5] Red Cross Anticoagulant Clin, The Hague, Netherlands
[6] Inspectorate Hlth Care, Drug Safety Unit, Rijswijk, Netherlands
关键词
overanticoagulation; coumarin anticoagulants; vitamin K-1; International Normalized Ratio; efficacy;
D O I
10.1046/j.1365-2141.1999.01196.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Oral vitamin K-1 is used for the treatment of excessive anticoagulation. Detailed information on changes in the International Normalized Ratio (INR) in response to vitamin K-1 is not available. We therefore measured the INR for the first 7 d following the oral intake of 1-5 mg of vitamin K-1 in 24 patients routinely treated with phenprocoumon who had an INR greater than or equal to 6.0 at presentation. On the first 2 d after administration of vitamin K-1, the mean INR decreased by 40% and 23% respectively After day 2, the day-to-day proportional change in the mean INR depended on the dose of vitamin K-1 and varied from a decrease of 12% to an increase of 21%. On day 7 the mean INR was higher than on day 2 in three out of five treatment groups. Between day 2 and day 7, in general, 32% of the patients had an INR value within the target zone, 25% had an INR value greater than or equal to 6.0 and 8% had an INR value <2.0. These findings suggest that our routine treatment of overanticoagulation in patients on phenprocoumon should be intensified to improve its efficacy.
引用
收藏
页码:241 / 245
页数:5
相关论文
共 9 条
[1]   OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH MECHANICAL HEART-VALVES [J].
CANNEGIETER, SC ;
ROSENDAAL, FR ;
WINTZEN, AR ;
VANDERMEER, FJM ;
VANDENBROUCKE, JP ;
BRIET, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (01) :11-17
[2]  
*FED NED TROMB, 1987, VAD POL BEH MET OR A
[3]  
Franke CL, 1997, ANN NEUROL, V42, P857
[4]   Oral vitamin K-1: An option to reduce warfarin's activity [J].
Harrell, CC ;
Kline, SS .
ANNALS OF PHARMACOTHERAPY, 1995, 29 (12) :1228-1232
[5]   ENZYME-INDUCTION BY PHENOBARBITONE AND VITAMIN-K1 DISPOSITION IN MAN [J].
PARK, BK ;
WILSON, AC ;
KAATZ, G ;
OHNHAUS, EE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (01) :94-97
[6]   PLASMA DISPOSITION OF VITAMIN-K1 IN RELATION TO ANTICOAGULANT POISONING [J].
PARK, BK ;
SCOTT, AK ;
WILSON, AC ;
HAYNES, BP ;
BRECKENRIDGE, AM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (05) :655-662
[7]   REVERSAL OF EXCESSIVE EFFECT OF REGULAR ANTICOAGULATION - LOW ORAL DOSE OF PHYTONADIONE (VITAMIN-K1) COMPARED WITH WARFARIN DISCONTINUATION [J].
PENGO, V ;
BANZATO, A ;
GARELLI, E ;
ZASSO, A ;
BIASIOLO, A .
BLOOD COAGULATION & FIBRINOLYSIS, 1993, 4 (05) :739-741
[8]   The Scylla and Charybdis of oral anticoagulant treatment [J].
Rosendaal, FR .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (08) :587-589
[9]  
WEIBERT RT, 1997, ANN INTERN MED, V125, P959